(1,3)-β-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study | Zendy

Brunella Posteraro | Zendy; Mario Tumbarello | Zendy; Gennaro De Pascale | Zendy; Elvira Liberto | Zendy; Maria Sole Vallecoccia | Zendy; Elena De Carolis | Zendy; Valentina Di Gravio | Zendy; Enrico Maria Trecarichi | Zendy; Maurizio Sanguinetti | Zendy; Massimo Antonelli | Zendy

Open Access

(1,3)-β-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study

Author(s) -

Brunella Posteraro,

Mario Tumbarello,

Gennaro De Pascale,

Elvira Liberto,

Maria Sole Vallecoccia,

Elena De Carolis,

Valentina Di Gravio,

Enrico Maria Trecarichi,

Maurizio Sanguinetti,

Massimo Antonelli

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw112

Subject(s) - observational study , critically ill , antifungal , medicine , intensive care medicine , fluconazole , echinocandin , invasive candidiasis , antifungal drugs , critical illness , dermatology

To determine the effects of a strategy that uses serum (1,3)-β-d-glucan (BDG) results for antifungal treatment of ICU patients at high risk of invasive candidiasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research